Related Experiment Video
Updated: Aug 8, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Acute coronary syndrome induced by capecitabine therapy
Namal Wijesinghe1, Paul I Thompson, Hugh McAlister
1Waikato Hospital, Cardiology Department, Private Bag 3200, Hamilton 2001, New Zealand. namalw@gmail.com
Abstract:
Capecitabine, a new member of the fluoropyrimidine family, is an orally administered drug that delivers fluorouracil (5-FU) selectively to the tumour. Although the cardiotoxicity of 5-FU is well documented, there is little published data about cardiovascular adverse effects of Capecitabine. This case highlights the possible development of acute coronary syndrome as a side effect of Capecitabine therapy.
Related Concept Videos
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies
Imaging Studies for Cardiovascular System V: CT
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...